liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Risk factors, prevention and treatment of weight gain associated with the use of antidepressants and antipsychotics: a state-of-the-art clinical review
Univ Ottawa, Canada; Ottawa Hosp, Canada; Charite, Germany.
Univ Padua, Italy.
Univ Padua, Italy; Univ Padua, Italy.
ASL Roma5, Italy.
Show others and affiliations
2024 (English)In: Expert Opinion on Drug Safety, ISSN 1474-0338, E-ISSN 1744-764X, Vol. 23, no 10, p. 1249-1269Article, review/survey (Refereed) Published
Abstract [en]

IntroductionPeople with severe mental illness have poor cardiometabolic health. Commonly used antidepressants and antipsychotics frequently lead to weight gain, which may further contribute to adverse cardiovascular outcomes.Areas coveredWe searched MEDLINE up to April 2023 for umbrella reviews, (network-)meta-analyses, trials and cohort studies on risk factors, prevention and treatment strategies of weight gain associated with antidepressants/antipsychotics. We developed 10 clinical recommendations.Expert opinionTo prevent, manage, and treat antidepressant/antipsychotic-related weight gain, we recommend i) assessing risk factors for obesity before treatment, ii) monitoring metabolic health at baseline and regularly during follow-up, iii) offering lifestyle interventions including regular exercise and healthy diet based on patient preference to optimize motivation, iv) considering first-line psychotherapy for mild-moderate depression and anxiety disorders, v)choosing medications based on medications' and patient's weight gain risk, vi) choosing medications based on acute vs long-term treatment, vii) using effective, tolerated medications, viii) switching to less weight-inducing antipsychotics/antidepressants where possible, ix) using early weight gain as a predictor of further weight gain to inform the timing of intervention/switch options, and x) considering adding metformin or glucagon-like peptide-1 receptor agonists, or topiramate(second-line due to potential adverse cognitive effects) to antipsychotics, or aripiprazole to clozapine or olanzapine.

Place, publisher, year, edition, pages
TAYLOR & FRANCIS LTD , 2024. Vol. 23, no 10, p. 1249-1269
Keywords [en]
Obesity; safety; antidepressant; antipsychotic; depression; schizophrenia; bipolar disorder; weight gain; psychiatry
National Category
Gynaecology, Obstetrics and Reproductive Medicine
Identifiers
URN: urn:nbn:se:liu:diva-208302DOI: 10.1080/14740338.2024.2396396ISI: 001319111600001PubMedID: 39225182Scopus ID: 2-s2.0-85204711879OAI: oai:DiVA.org:liu-208302DiVA, id: diva2:1904329
Available from: 2024-10-09 Created: 2024-10-09 Last updated: 2025-03-01

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Search in DiVA

By author/editor
Dragioti, Elena
By organisation
Division of Prevention, Rehabilitation and Community MedicineFaculty of Medicine and Health SciencesPain and Rehabilitation Center
In the same journal
Expert Opinion on Drug Safety
Gynaecology, Obstetrics and Reproductive Medicine

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 62 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf